MA54225A - Procédés de préparation de dérivés de benzodiazépine cytotoxiques - Google Patents
Procédés de préparation de dérivés de benzodiazépine cytotoxiquesInfo
- Publication number
- MA54225A MA54225A MA054225A MA54225A MA54225A MA 54225 A MA54225 A MA 54225A MA 054225 A MA054225 A MA 054225A MA 54225 A MA54225 A MA 54225A MA 54225 A MA54225 A MA 54225A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- benzodiazepine derivatives
- cytotoxic benzodiazepine
- preparing cytotoxic
- preparing
- Prior art date
Links
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 title 1
- 150000001557 benzodiazepines Chemical class 0.000 title 1
- 231100000433 cytotoxic Toxicity 0.000 title 1
- 230000001472 cytotoxic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862758819P | 2018-11-12 | 2018-11-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54225A true MA54225A (fr) | 2021-09-22 |
Family
ID=68808530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054225A MA54225A (fr) | 2018-11-12 | 2019-11-11 | Procédés de préparation de dérivés de benzodiazépine cytotoxiques |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10913713B2 (fr) |
| EP (2) | EP3880656B1 (fr) |
| JP (1) | JP2022512936A (fr) |
| KR (1) | KR20210099010A (fr) |
| CN (1) | CN113166053A (fr) |
| AU (1) | AU2019381628A1 (fr) |
| CA (1) | CA3119544A1 (fr) |
| IL (2) | IL308670A (fr) |
| MA (1) | MA54225A (fr) |
| SG (1) | SG11202104423XA (fr) |
| TW (1) | TWI849000B (fr) |
| WO (1) | WO2020102053A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019381628A1 (en) | 2018-11-12 | 2021-05-27 | Immunogen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
| EP4384502A1 (fr) | 2021-08-13 | 2024-06-19 | ImmunoGen, Inc. | Procédés améliorés de préparation de dérivés de benzodiazépine cytotoxiques |
| AU2023298568A1 (en) | 2022-06-30 | 2025-01-09 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0708818D0 (en) * | 2007-05-08 | 2007-06-13 | Portela & Ca Sa | Compounds |
| SI2675480T1 (sl) | 2011-02-15 | 2019-05-31 | Immunogen, Inc. | Metode priprave konjugatov |
| SI3313845T1 (sl) * | 2015-06-29 | 2021-01-29 | Immunogen, Inc. | Konjugati spremenjenih protiteles cisteina |
| SMT202100092T1 (it) * | 2015-06-29 | 2021-03-15 | Immunogen Inc | Anticorpi anti-cd123 e loro coniugati e derivati |
| EP3778602B1 (fr) * | 2015-07-21 | 2023-07-12 | ImmunoGen, Inc. | Procédés de préparation de dérivés de benzodiazépine cytotoxique |
| RS65120B1 (sr) * | 2015-11-25 | 2024-02-29 | Immunogen Inc | Farmaceutske formulacije i postupci za njihovu upotrebu |
| HRP20230002T1 (hr) | 2017-01-25 | 2023-02-17 | Immunogen, Inc. | Postupci pripreme citotoksičnih derivata benzodiazepina |
| WO2019133652A1 (fr) * | 2017-12-28 | 2019-07-04 | Immunogen, Inc. | Dérivés de benzodiazépine |
| AU2019381628A1 (en) | 2018-11-12 | 2021-05-27 | Immunogen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
-
2019
- 2019-11-11 AU AU2019381628A patent/AU2019381628A1/en not_active Abandoned
- 2019-11-11 KR KR1020217017973A patent/KR20210099010A/ko not_active Withdrawn
- 2019-11-11 MA MA054225A patent/MA54225A/fr unknown
- 2019-11-11 CA CA3119544A patent/CA3119544A1/fr active Pending
- 2019-11-11 IL IL308670A patent/IL308670A/en unknown
- 2019-11-11 IL IL283047A patent/IL283047B2/en unknown
- 2019-11-11 US US16/679,593 patent/US10913713B2/en active Active
- 2019-11-11 EP EP19816995.5A patent/EP3880656B1/fr active Active
- 2019-11-11 WO PCT/US2019/060679 patent/WO2020102053A1/fr not_active Ceased
- 2019-11-11 SG SG11202104423XA patent/SG11202104423XA/en unknown
- 2019-11-11 CN CN201980074349.0A patent/CN113166053A/zh active Pending
- 2019-11-11 JP JP2021524308A patent/JP2022512936A/ja not_active Ceased
- 2019-11-11 TW TW108140770A patent/TWI849000B/zh not_active IP Right Cessation
- 2019-11-11 EP EP24164117.4A patent/EP4365173A3/fr not_active Withdrawn
-
2021
- 2021-01-07 US US17/143,723 patent/US11591296B2/en active Active
-
2023
- 2023-01-19 US US18/098,834 patent/US20230286914A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN113166053A (zh) | 2021-07-23 |
| TWI849000B (zh) | 2024-07-21 |
| US11591296B2 (en) | 2023-02-28 |
| IL308670A (en) | 2024-01-01 |
| IL283047B1 (en) | 2023-12-01 |
| KR20210099010A (ko) | 2021-08-11 |
| CA3119544A1 (fr) | 2020-05-22 |
| US20200172481A1 (en) | 2020-06-04 |
| US20230286914A1 (en) | 2023-09-14 |
| WO2020102053A8 (fr) | 2020-06-18 |
| TW202033498A (zh) | 2020-09-16 |
| WO2020102053A1 (fr) | 2020-05-22 |
| US20210230114A1 (en) | 2021-07-29 |
| EP3880656A1 (fr) | 2021-09-22 |
| JP2022512936A (ja) | 2022-02-07 |
| EP4365173A2 (fr) | 2024-05-08 |
| US10913713B2 (en) | 2021-02-09 |
| SG11202104423XA (en) | 2021-05-28 |
| IL283047A (en) | 2021-06-30 |
| EP4365173A3 (fr) | 2024-07-17 |
| IL283047B2 (en) | 2024-04-01 |
| AU2019381628A1 (en) | 2021-05-27 |
| EP3880656B1 (fr) | 2024-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3980073A4 (fr) | Procédés de préparation de complexes protéine-oligonucléotide | |
| MA49752A (fr) | Procédés de préparation de composés de pyrrolidine | |
| EP3826682A4 (fr) | Supports dérivés de cholix pour administration orale de chargement hétérologue | |
| EP3331896A4 (fr) | Procédés de préparation d'acides biliaires et de leurs dérivés | |
| MA54253A (fr) | Procédé de préparation de dérivés de 2-chloro-4-hétéroaryl-pyridimidines | |
| MA54254A (fr) | Dérivés de benzodiazépine cytotoxique | |
| EP3833343A4 (fr) | Dérivés hétérocycliques de flavone, compositions et procédés associés | |
| EP3481827A4 (fr) | Dérivés d'imidazo[1,2-a]pyridine, leurs procédés de préparation et leur utilisation | |
| EP3969457A4 (fr) | Procédés de préparation d'indoles macrocycliques | |
| CY1122553T1 (el) | Μεθοδοι παρασκευης κυτταροτοξικων παραγωγων βενζοδιαζεπινης | |
| EP3980013A4 (fr) | Procédés de préparation de composés aminopyrimidine | |
| IL287405A (en) | Methods of preparing cytotoxic benzodiazepine derivatives | |
| EP3658552A4 (fr) | Procédé amélioré pour la préparation de dérivés d'aminopyrimidine | |
| EP3863612A4 (fr) | Procédés de préparation de cyclooctènes fonctionnalisés | |
| EP3597674A4 (fr) | Procédé de préparation de copolymère | |
| MA54228A (fr) | Procédés de préparation de dérivés de benzodiazépine cytotoxiques | |
| MA54396A (fr) | Procédé de préparation de n-phénylpyrazole-1-carboxamides | |
| EP3341359A4 (fr) | Procédé de préparation d'aprémilast | |
| EP3696168A4 (fr) | Procédé de préparation de 2-chloro-5-trifluorométhylpyridine | |
| IL283047A (en) | Methods for preparing cytotoxic benzodiazepine derivatives | |
| EP3390368A4 (fr) | Procédés de préparation de 5,6-dihydro-6-phénylbenzo[f]isoquinoléine-2-amine substituée | |
| MA56504A (fr) | Dérivés de pyridin-3-yle | |
| MA51510A (fr) | Procédés de préparation de dérivés d'indolinobenzodiazépine | |
| EP3505525A4 (fr) | Procédé de préparation de rubusoside | |
| EP3733651A4 (fr) | Procédé de préparation de calcobutrol |